Theratechnologies (NASDAQ:THTX - Get Free Report) was downgraded by Jones Trading from a "strong-buy" rating to a "hold" rating in a note issued to investors on Thursday, Marketbeat Ratings reports.
Theratechnologies Stock Performance
NASDAQ THTX traded up $0.77 during trading hours on Thursday, hitting $3.13. 10,560,877 shares of the company's stock were exchanged, compared to its average volume of 864,044. The business's 50 day moving average is $2.61 and its 200-day moving average is $2.07. Theratechnologies has a 12-month low of $1.12 and a 12-month high of $3.20. The firm has a market capitalization of $143.92 million, a P/E ratio of -39.13 and a beta of 0.55.
Institutional Trading of Theratechnologies
Hedge funds have recently added to or reduced their stakes in the business. Raymond James Financial Inc. acquired a new stake in Theratechnologies in the 4th quarter worth about $27,000. Bank of America Corp DE boosted its stake in Theratechnologies by 1,416.7% in the 4th quarter. Bank of America Corp DE now owns 16,487 shares of the company's stock worth $30,000 after buying an additional 15,400 shares during the last quarter. JPMorgan Chase & Co. acquired a new stake in Theratechnologies in the 4th quarter worth about $33,000. BNP Paribas Financial Markets acquired a new stake in Theratechnologies in the 4th quarter worth about $36,000. Finally, Virtu Financial LLC acquired a new stake in Theratechnologies in the 4th quarter worth about $40,000.
Theratechnologies Company Profile
(
Get Free Report)
Theratechnologies Inc, a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen.
Further Reading
Before you consider Theratechnologies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Theratechnologies wasn't on the list.
While Theratechnologies currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
